Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant versus adjuvant pembrolizumab-based therapy in resectable stage II-IIIA non-small cell lung cancer
ChiCTR2200067160Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab, paclitaxel and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Event-free survival. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200067160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067160.